Full-Time

Market Integration

Updated on 9/17/2026

Deadline 9/25/26
Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Remote in USA + 2 more

More locations: Carrollton, TX, USA | Conshohocken, PA, USA

Hybrid

Remote work is limited to the Central or Eastern Time Zone.

Bachelor's, Master's

Category
IT Operations
Required Skills
Distributed Systems
Mergers & Acquisitions (M&A)

Get referred to Cencora

See people who can refer or advise you

Requirements
  • A bachelor's degree in information technology, computer science, information systems, business administration, or a related field is required.
  • At least 12 years of experience in technology strategy, mergers and acquisitions technology, enterprise architecture, transformation, or a related field is required.
  • At least 8 years of experience in a management capacity is required.
  • Deep understanding of information technology infrastructure, cloud management, network architecture, and distributed systems is required.
  • Expertise in enterprise information technology governance, regulatory compliance, and risk mitigation during mergers, acquisitions, and divestitures is required.
  • Strong knowledge of information technology governance frameworks, security protocols, and regulatory standards, including Sarbanes-Oxley compliance, is required.
  • Ability to establish and enforce accountability measures for infrastructure management during mergers, acquisitions, and divestitures is required.
  • Expertise in operational continuity, disaster recovery, and resilience planning for information technology infrastructure is required.
  • Solid change-management skills are required to ensure smooth transitions and adoption of integrated systems.
  • Proven ability to align workforce structures and foster employee engagement during mergers, acquisitions, and divestitures is required.
  • Experience negotiating and managing vendor relationships to deliver high-quality outcomes is required.
Responsibilities
  • Develop and implement information technology strategies aligned with Market Integration objectives, focusing on governance, security, and accountability for acquired or divested infrastructure.
  • Lead strategic technology planning to ensure application resilience and operational continuity during merger, acquisition, and divestiture activities.
  • Define and oversee technology and resource-integration roadmaps aligned with business priorities and market-integration goals.
  • Oversee the engineering, deployment, and operation of critical information technology infrastructure systems, including networks, data centers, and operational facilities, during integration or divestiture.
  • Drive accountability for infrastructure governance and security across acquired or divested assets and ensure compliance with regulatory standards and security protocols.
  • Partner with internal teams and external stakeholders to maintain data-center resilience, operational reliability, and business continuity throughout transitions.
  • Establish and enforce governance frameworks for infrastructure-related activities during mergers, acquisitions, and divestitures.
  • Lead efforts to ensure information technology regulatory compliance, including General Data Protection Regulation and Sarbanes-Oxley compliance, and implement security measures to protect sensitive data and systems.
  • Collaborate with the Market Integration team to develop policies, processes, and standards for infrastructure management across acquired or divested entities.
  • Identify and mitigate risks to information technology infrastructure during transitions to ensure operational continuity.
  • Develop and implement disaster-recovery and business-continuity plans for data centers and operational facilities.
  • Monitor and measure service performance and implement improvements to optimize operational outcomes.
  • Partner with the Market Integration team, federated infrastructure teams, and other business units to align objectives and integrate infrastructure.
  • Advise leadership on infrastructure governance, security, and operational continuity during merger, acquisition, and divestiture activities.
  • Oversee employee-resource integration across merged or divested entities, including organizational structures, roles, and responsibilities.
  • Collaborate with Human Resources and leadership teams to onboard, train, and align employees with organizational goals, technology platforms, and governance frameworks.
  • Manage vendor relationships and service delivery supporting infrastructure integration and operational continuity.
  • Negotiate contracts and ensure vendors meet performance expectations during merger, acquisition, and divestiture activities.
  • Broker services within information technology and with external vendors to align with market-integration objectives.
  • Design and implement communication, process, and educational plans to mitigate disruption during merger, acquisition, and divestiture activities.
  • Lead change-management initiatives for infrastructure and personnel transitions.
  • Identify and address obstacles to change and foster employee buy-in and engagement.
  • Develop and manage information technology budgets for merger, acquisition, and divestiture activities.
  • Monitor financial performance and implement improvements to optimize integration outcomes.
  • Provide input on financial parameters that drive service costs during infrastructure transitions.
Desired Qualifications
  • A master's degree in information technology, business administration, information systems, or a related field is preferred.
  • Certification in enterprise architecture, project management, or change-management disciplines, or equivalent certification, is preferred.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 Q3 revenue reached $84.8 billion, and EPS guidance rose to $17.75-$17.95.
  • Cencora completed OneOncology in February 2026, strengthening specialty-pharmacy and oncology economics.
  • A $7 billion revolver and $1 billion buyback show lenders and management backing execution.

What critics are saying

  • Opioid litigation still carries a $4.2 billion accrued liability through 2039.
  • Maryland courts vacated Baltimore's $152 million verdict, but appeals can revive distributor exposure.
  • ASP rule changes and 340B guidance threaten community-oncology margins by 2028, hitting OneOncology.

What makes Cencora unique

  • Cencora pairs drug distribution with OneOncology, deepening specialty-care workflow integration.
  • Its global network spans U.S. Healthcare Solutions and International Healthcare Solutions across 51,000 employees.
  • Nucleus inventory tools and cell-gene therapy enablement embed Cencora inside provider operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.